Sinocare Inc (SHE: 300298), a China-based medical technology company, has announced that its continuous glucose monitoring system (CGMS), TRUE VIE CGMS, has entered the 510(k) substantive review stage at the US Food and Drug Administration (FDA). This milestone follows the successful passage of the initial acceptance review for the FDA 510(k) filing.
TRUE VIE CGMS: A Cutting-Edge Diabetes Management Device
The TRUE VIE CGMS is a state-of-the-art continuous glucose monitoring device designed for diabetes management in individuals aged two years and above. This innovative system is intended to replace the traditional finger prick blood glucose detection methods, offering a more convenient and less invasive approach to diabetes treatment decision-making.
Integration with Digital Connection Equipment
The TRUE VIE CGMS is also designed with the capability to communicate with digital connection equipment, enabling it to be used as a standalone device or in combination with such equipment for comprehensive diabetes management. This feature positions the system at the forefront of digital health solutions for diabetes care.-Fineline Info & Tech
